Akero Therapeutics Inc

Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

LOS ANGELES, CA / ACCESSWIRE / November 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akero Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

-- Phase 3 SYNCHRONY studies actively screening and on track to begin enrolling by the end of 2023 -- SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2023 and provided business updates.

Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and support continued development of EFX for treatment of cirrhosis due to NASH/MASH

Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD's The Liver Meeting® 2023

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced management will present at the following investor conferences this month:

Akero Therapeutics to Present at Upcoming Healthcare Conferences in November

LOS ANGELES, CA / ACCESSWIRE / October 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akero Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced management will present virtually at the H.C. Wainwright 7th Annual NASH Conference on Tuesday, October 24, 2023, at 12:00 p.m. E.T.

Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

Akero only has one drug in clinical trials. The company said the drug didn't meet its primary endpoint of slowing NASH.

Why Akero Therapeutics Shares Are Slumping This Week

Data from a mid-stage study shows that Akero Therapeutics' (AKRO) lead candidate failed to achieve statistical significance in its primary endpoint of fibrosis improvement in cirrhotic NASH patients.

Akero (AKRO) Slumps 63% on Mixed Results From NASH Study

Akero Therapeutics' share price is tanking after biotech's NASH drug fails to meet its primary endpoint in a Phase 2B study. Despite the setback, AKRO stock is still trading higher than it was in September 2022, before another Phase 2 study succeeded in earlier stage fibrosis. Akero may have set its primary endpoint bar too high in this latest study, and results could still improve at 96 weeks.

Akero Therapeutics: Contrarian Buy Opportunity As Stock Tanks On 'NASH Dash' Data

Akero Therapeutics Inc shares lost roughly two-thirds of their value Tuesday morning after the company released a disappointing update on its fatty liver disease treatment.  A study found that just 22% to 24% of the patients with compensated cirrhosis due to NASH (nonalcoholic steatohepatitis) who received Akero's treatment efruxifermin saw at least a one-stage improvement in liver fibrosis, according to a statement.

Akero Therapeutics Inc stock tanks after NASH liver treatment study disappoints

Akero's experimental NASH drug efruxifermin (EFX) missed its primary endpoint in a phase 2b study. However, statistically significant improvement was seen in NASH resolution with patients receiving EFX.

Why Akero Therapeutics Stock Is Crashing Today

Akero Therapeutics Inc (NASDAQ:AKRO) is plummeting to 52-week lows, after its treatment for severe fatty liver disease, efruxifermin, missed its main goal in a mid-stage trial.

Biotech Stock Sinks After Disappointing Trial

Akero Therapeutics Inc (NASDAQ: AKRO) crashed more than 65% this morning after reporting interim results of SYMMETRY – a Phase 2b study of its non-alcoholic steatohepatitis (NASH) candidate. Akero Therapeutics' EFX failed a key test On Tuesday, the biotech firm said its Efruxifermin did not perform significantly better than placebo in the said clinical trial.

Akero Therapeutics stock crashed 65% on Tuesday: what happened?

89bio Inc

AKRO stock and ETNB stock crashed Tuesday after Akero's treatment for the liver disease, NASH, fell short in a midstage study.

Why Akero Therapeutics Lost More Than Half Its Value And Dragged Down 89bio

Akero Therapeutics (NASDAQ: AKRO ) stock is falling hard on Tuesday after the company failed to impress investors with its latest clinical trial results. The bad news comes from the company's Phase 2b Symmetry study evaluating the effectiveness of efruxifermin in patients with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH).

Why Is Akero Therapeutics (AKRO) Stock Down 58% Today?

Akero Therapeutics Inc. shares AKRO, -3.56% fell more than 60% premarket on Tuesday after the company released an update on its lead product candidate, a treatment for nonalcoholic steatohepatitis, a form of fatty liver disease.

Akero Therapeutics shares plunge on liver disease treatment's mixed results

Akero Therapeutics said on Tuesday a mid-stage trial for its drug to treat a type of fatty liver disease showed improvement in patients, but the results were not statistically significant, sending its shares down 63% in premarket trading.

Akero's drug for fatty liver disease misses main trial goal

22% (28mg EFX) and 24% (50mg EFX) of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to 14% for placebo

Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lip

Investor webcast on Tuesday, October 10 at 8:00 a.m. ET to present clinical data Investor webcast on Tuesday, October 10 at 8:00 a.m. ET to present clinical data

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

As previously reported, the study met its primary endpoint of improvement in liver fibrosis without worsening of NASH at week 24, and key secondary endpoints including NASH resolution without worsening of fibrosis

Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology

CymaBay Therapeutics

MoonLake Immunotherapeutics

Olema Pharmaceuticals

Option Care Health

Rapt Therapeutics Inc

Sensus Healthcare

While the health innovation space presents wild risks, you could potentially swing the odds in your favor with strong buy biotech stocks. Specifically, these ideas represent publicly traded biotechnology firms that enjoy the highest possible consensus rating among Wall Street analysts.

7 ‘Strong Buy' Biotech Stocks to Rejuvenate Your Portfolio

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the following investor conferences this month:

Akero Therapeutics to Present at Upcoming Healthcare Conferences in September

Akero Therapeutics could become a leader in non-alcoholic steatohepatitis (NASH) treatment, according to analysts at UBS who have initiated coverage on the stock with a ‘Buy' rating. NASH is an advanced form of non-alcoholic fatty liver disease characterized by inflammation and fibrosis of the liver that can progress to cirrhosis, liver failures, and liver cancer.

Akero Therapeutics poised to be leader in NASH with upcoming trial data readout potential stock catalyst

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that all samples and data required for a readout of topline results from the Phase 2b SYMMETRY study have been collected, which supports the expected timing of readout in October of this year. The topline week 36 results from the study, evaluating treatment of patients with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH), will include histology and changes from baseline in non-invasive measures of fibrosis, glycemic control, and lipoproteins as well as safety and tolerability.

Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023

-- Positive Results from Phase 2b SYMMETRY Cohort D, an expansion cohort of Type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 receptor agonist, reported during the second quarter of 2023 -- -- Phase 3 SYNCHRONY studies on track to begin enrolling in the second half of 2023 --

News for Akero Therapeutics Inc Stock (AKRO)